Trillium Therapeutics Inc. (TRIL): Price and Financial Metrics

Trillium Therapeutics Inc. (TRIL)

Today's Latest Price: $6.53 USD

0.76 (13.17%)

Updated May 29 3:32pm

Add TRIL to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

TRIL Daily Price Range
TRIL 52-Week Price Range

TRIL Stock Price Chart More Charts

TRIL Price/Volume Stats

Current price $6.53 52-week high $7.97
Prev. close $5.77 52-week low $0.24
Day low $6.03 Volume 5,599,127
Day high $6.99 Avg. volume 4,104,268
50-day MA $4.93 Dividend yield N/A
200-day MA $2.42 Market Cap 539.92M

Trillium Therapeutics Inc. (TRIL) Company Bio

Trillium Therapeutics develops therapies for the treatment of cancer. The company was founded in 2004 and is based in Toronto, Canada.

TRIL Latest News Stream

Event/TimeNews Detail
Loading, please wait...

TRIL Latest Social Stream

Loading social stream, please wait...

View Full TRIL Social Stream

Latest TRIL News From Around the Web

Below are the latest news stories about Trillium Therapeutics Inc that investors may wish to consider to help them evaluate TRIL as an investment opportunity.

Trillium Therapeutics Reports First Quarter 2020 Financial and Operating Results

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three months ended March 31, 2020. On January 7, Trillium provided a data update on the ongoing dose escalation studies.

Yahoo | May 15, 2020

Trillium Therapeutics to Present Data on CD47 Blocker TTI-622 in Advanced Relapsed or Refractory Lymphoma at the ASCO20 Virtual Scientific Program

CAMBRIDGE, Mass., May 13, 2020 -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative.

Yahoo | May 13, 2020

Trillium Therapeutics Announces “At-The-Market” Equity Program

CAMBRIDGE, Mass., May 06, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage…

GlobeNewswire | May 6, 2020

Is Trillium Therapeutics (TRIL) Stock Outpacing Its Medical Peers This Year?

Is (TRIL) Outperforming Other Medical Stocks This Year?

Zacks Investment Research | March 26, 2020

The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 2) Forty Seven Inc (NASDAQ: FTSV )( announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD )) IGM Biosciences Inc (NASDAQ: IGMS ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Karyopharm Therapeutics Inc (NASDAQ: KPTI )(announced positive late-stage results for selinexor) Passage Bio Inc (NASDAQ: PASG )(IPOed Friday) Syneos Health Inc (NASDAQ: SYNH ) Trillium Therapeutics Inc (NASDAQ: TRIL )(moved in sympathy with Forty Seven, as it has a similar drug in the pipeline for solid tumor) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 2) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zenta...

Benzinga | March 3, 2020

Read More 'TRIL' Stories Here

TRIL Price Returns

1-mo 40.73%
3-mo 29.31%
6-mo 1,876.39%
1-year 1,556.94%
3-year 29.31%
5-year -70.53%
YTD 533.98%
2019 -39.77%
2018 -76.41%
2017 28.32%
2016 -55.19%
2015 40.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7835 seconds.